Substituted 2-pyrrolinone inhibitors of HIV-1 integrase

被引：27

作者：

Dayam, Raveendra ^{[1
]}

Al-Mawsawi, Laith Q. ^{[1
]}

Neamati, Nouri ^{[1
]}

机构：

[1] Univ So Calif, Sch Pharm, Dept Pharmaceut Sci & Pharmacol, Los Angeles, CA 90089 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 22期

关键词：

HIV-1; integrase; beta-diketoacids; pharmacophore; substituted pyrrolin-2-ones; substructure; structure-activity relationship analysis;

D O I：

10.1016/j.bmcl.2007.09.061

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The beta-diketoacid class of HIV-1 integrase (IN) inhibitors represent the first potent class of compounds specific for the strand transfer catalytic activity of the viral enzyme. Previously, utilizing a beta-diketoacid pharmacophore as a search query, we identified a substituted 2-pyrrolinone with modest IN inhibitory activity from a database of small-molecules [Dayam, R.; Sanchez, T.; Neamati, N. J. Med. Chem. 2005, 48, 8009]. In efforts to optimize this class of IN inhibitors, we carried out a structure-activity relationship analysis around the 2-pyrrolinone core. Here, we present a new class of 2-pyrrolinone IN inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：6155 / 6159

页数：5

共 14 条

[1] Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity [J].

Al-Mawsawi, Laith Q. ;

Sechi, Mario ;

Neamati, Nouri .

FEBS LETTERS, 2007, 581 (06) :1151-1156

[2]

Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206

[3]

Brown P. O., 1997, P161

[4] ACTIVITIES OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INTEGRATION PROTEIN INVITRO - SPECIFIC CLEAVAGE AND INTEGRATION OF HIV DNA [J].

BUSHMAN, FD ;

CRAIGIE, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1339-1343

[5] HIV-1 integrase inhibitors: 2003-2004 update [J].

Dayam, R ;

Detig, FX ;

Neamati, N .

MEDICINAL RESEARCH REVIEWS, 2006, 26 (03) :271-309

[6] Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase [J].

Dayam, R ;

Sanchez, T ;

Neamati, N .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (25) :8009-8015

[7] Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].

DeJesus, Edwin ;

Berger, Daniel ;

Markowitz, Martin ;

Cohen, Calvin ;

Hawkins, Trevor ;

Ruane, Peter ;

Elion, Richard ;

Farthing, Charles ;

Zhong, Lijie ;

Cheng, Andrew K. ;

McColl, Dainian ;

Kearney, Brian P. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5

[8] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[9] Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells [J].

Hazuda, DJ ;

Felock, P ;

Witmer, M ;

Wolfe, A ;

Stillmock, K ;

Grobler, JA ;

Espeseth, A ;

Gabryelski, L ;

Schleif, W ;

Blau, C ;

Miller, MD .

SCIENCE, 2000, 287 (5453) :646-650

[10] Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].

Markowitz, Martin ;

Morales-Ramirez, Javier O. ;

Nguyen, Bach-Yen ;

Kovacs, Colin M. ;

Steigbigel, Roy T. ;

Cooper, David A. ;

Liporace, Ralph ;

Schwartz, Robert ;

Isaacs, Robin ;

Gilde, Lucinda R. ;

Penning, Larissa ;

Zhao, Jing ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515

← 1 2 →